腦膜炎雙球菌疫苗市場規模、佔有率及成長分析（按類型、最終用戶和地區分類）－2026年至2033年產業預測

預計到 2024 年，腦膜炎雙球菌疫苗市值將達到 37.1 億美元，到 2025 年將成長至 39.4 億美元，到 2033 年將成長至 63.3 億美元，在預測期（2026-2033 年）內複合年成長率為 6.1%。

由於全球腦膜炎發生率不斷上升，腦膜炎雙球菌疫苗市場預計將迎來顯著成長。據估計，全球每年約有120萬例細菌性腦膜炎病例報告。疫苗接種活動的加強和公眾對該疾病的認知進一步推動了市場擴張。各國腦膜炎協會等重要的政府和非政府組織在研發和製定新的預防策略方面發揮關鍵作用。目前市售的腦膜炎雙球菌疫苗涵蓋多種菌株，包括A、B、C、W-135和Y型，並提供單價和多價疫苗兩種選擇。此外，將這些疫苗納入國家免疫規劃的趨勢以及疫苗技術的進步預計將推動市場成長，但嚴格的監管準則可能會帶來挑戰。

推動腦膜炎雙球菌疫苗市場發展的因素

腦膜炎球菌疫苗市場的主要驅動力是全球腦膜炎球菌病菌感染的不斷增加。由腦膜炎奈瑟菌引起的腦膜炎和敗血症死亡率高，並可能導致嚴重的長期併發症，包括神經損傷。因此，醫療機構強調透過接種疫苗進行預防的重要性。撒哈拉以南非洲地區，即所謂的“腦膜炎帶”，尤其容易受到這些感染疾病。人們對腦膜炎球菌感染日益成長的認知以及對有效預防措施的迫切需求，正在推動對腦膜炎球菌疫苗的需求，並促進市場成長。

腦膜炎雙球菌疫苗的市場限制

腦膜炎雙球菌疫苗市場面臨的主要障礙是其生產和分銷高成本。腦膜炎球菌病菌感染高發生率的低收入地區難以取得先進疫苗，尤其是採用重組結合技術的疫苗。儘管政府機構和非政府組織提供補貼，但疫苗價格仍然是一個持續存在的挑戰，阻礙了疫苗的廣泛接種。這種經濟障礙不僅影響疫苗的可及性，也為在最需要的人群中實現全面疫苗接種覆蓋率帶來了挑戰。

腦膜炎雙球菌疫苗市場趨勢

腦膜炎雙球菌疫苗市場正呈現出顯著的趨勢，即採用能夠抵禦多種菌株的聯合疫苗。對涵蓋A、C、W和Y群的四價疫苗的需求不斷成長，顯示人們希望獲得更廣泛的保護，這有效地簡化了疫苗接種程序。這種轉變不僅減少了多劑接種帶來的後勤挑戰，也有助於提高病患的疫苗接種依從性。隨著醫護人員和患者都認知到全面保護的益處，預計這一趨勢將對整體公共衛生產生積極影響，並有助於提高全球疫苗接種策略的效率。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特的分析和影響

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 監管環境
• 專利分析
• 案例研究

全球腦膜炎雙球菌疫苗市場規模（按疫苗類型和複合年成長率分類）（2026-2033 年）

• 多醣體疫苗
• 結合疫苗
  • 四價
  • 二價
  • 單價疫苗
• 聯合疫苗
• B型腦膜炎雙球菌疫苗

全球腦膜炎雙球菌疫苗市場規模（按品牌和複合年成長率分類）（2026-2033 年）

• 梅納克特拉
• 門貝奧
• 尼門里克斯
• 貝克塞洛
• 真正的會員
• 其他

全球腦膜炎雙球菌疫苗市場規模（依年齡層分類）及複合年成長率（2026-2033 年）

• 嬰幼兒
• 兒童
• 青春期
• 成人

全球腦膜炎雙球菌疫苗市場規模（依最終用戶分類）及複合年成長率（2026-2033 年）

• 醫院
• 診所
• 疫苗接種中心
• 其他

全球腦膜炎雙球菌疫苗市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 英國
  • 德國
  • 西班牙
  • 法國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2021-2023年營收年比比較

主要企業簡介

• Pfizer Inc.
• GlaxoSmithKline plc
• Sanofi SA
• Merck & Co., Inc.
• Novartis AG
• CSL Limited
• Serum Institute of India Pvt. Ltd.
• Biomed Pvt. Ltd.
• Bharat Biotech
• Biological E. Limited
• Hualan Biological Engineering Inc.
• Walvax Biotechnology Co., Ltd.
• Chongqing Zhifei Biological Products Co., Ltd.
• Emergent BioSolutions Inc.
• Incepta Vaccine Ltd.
• Panacea Biotec Ltd.
• LG Chem Ltd.
• Mitsubishi Tanabe Pharma Corporation
• Valneva SE
• Vaxart, Inc.

結論與建議

Meningococcal Vaccines Market size was valued at USD 3.71 Billion in 2024 and is poised to grow from USD 3.94 Billion in 2025 to USD 6.33 Billion by 2033, growing at a CAGR of 6.1% during the forecast period (2026-2033).

The meningococcal vaccines market is poised for significant growth, driven by the rising incidence of meningitis globally, with an estimated 1.2 million cases of bacterial meningitis reported. Increased immunization initiatives and heightened awareness about the disease are further bolstering market expansion. Key government and non-government organizations, such as national meningitis associations, play a crucial role in promoting research and developing new prevention strategies. The available meningococcal vaccines target various strains, including A, B, C, W-135, and Y, with options for both monovalent and multivalent formulations. Moreover, the growing trend towards incorporating these vaccines into national immunization programs and the advancement in vaccine technology are expected to drive market momentum, even as stringent regulatory guidelines may pose challenges.

Top-down and bottom-up approaches were used to estimate and validate the size of the Meningococcal Vaccines market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Meningococcal Vaccines Market Segments Analysis

Global Meningococcal Vaccines Market is segmented by vaccine type, brand, age group, end user and region. Based on vaccine type, the market is segmented into polysaccharide vaccines, conjugate vaccines (quadrivalent, bivalent, monovalent), combination vaccines and men b vaccines. Based on brand, the market is segmented into menactra, menveo, nimenrix, bexsero, trumenba and others. Based on age group, the market is segmented into infants, children, adolescents and adults. Based on end user, the market is segmented into hospitals, clinics, vaccination centers and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Meningococcal Vaccines Market

The meningococcal vaccines market is significantly propelled by the increasing occurrence of meningococcal diseases worldwide. Conditions like meningitis and septicemia caused by Neisseria meningitis are associated with high mortality rates and can result in serious long-term complications, including neurological damage. Consequently, health care providers are emphasizing the importance of prevention through vaccination. Certain areas, particularly Sub-Saharan Africa, are recognized as "meningitis belts," where the prevalence of these infections is notably high. This rising awareness and the urgent need for effective preventive measures are driving the demand for meningococcal vaccines, thereby expanding the market.

Restraints in the Meningococcal Vaccines Market

A significant obstacle in the meningococcal vaccines market is the elevated costs linked to both production and distribution. The availability of advanced vaccines, particularly those utilizing conjugated recombinant technologies, is limited in low-income regions that experience a high incidence of meningococcal disease. Despite the support from governmental and non-governmental organizations in the form of subsidies, the issue of affordability persists, impeding extensive vaccination initiatives. This financial barrier not only affects access to vaccines but also challenges efforts to achieve comprehensive immunization coverage in populations that need it the most.

Market Trends of the Meningococcal Vaccines Market

The meningococcal vaccines market is witnessing a significant trend towards the adoption of combination vaccines, which offer protection against multiple strains of the bacteria. The growing preference for quadrivalent vaccines that target serogroups A, C, W, and Y highlights a demand for broader coverage, effectively simplifying vaccination regimens. This shift not only alleviates logistical challenges associated with administering multiple doses but also enhances patient compliance with immunization schedules. As healthcare providers and patients alike recognize the benefits of comprehensive protection, the trend is expected to contribute positively to overall public health outcomes and streamline vaccination strategies worldwide.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Driver & Opportunities
  • Restraints & Challenges
• Porters Analysis & Impact
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Patent Analysis
• Case Studies

Global Meningococcal Vaccines Market Size by Vaccine Type & CAGR (2026-2033)

• Market Overview
• Polysaccharide Vaccines
• Conjugate Vaccines
  • Quadrivalent
  • Bivalent
  • Monovalent
• Combination Vaccines
• Men B Vaccines

Global Meningococcal Vaccines Market Size by Brand & CAGR (2026-2033)

• Market Overview
• Menactra
• Menveo
• Nimenrix
• Bexsero
• Trumenba
• Others

Global Meningococcal Vaccines Market Size by Age Group & CAGR (2026-2033)

• Market Overview
• Infants
• Children
• Adolescents
• Adults

Global Meningococcal Vaccines Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Clinics
• Vaccination Centers
• Others

Global Meningococcal Vaccines Market Size & CAGR (2026-2033)

• North America (Vaccine Type, Brand, Age Group, End User)
  • US
  • Canada
• Europe (Vaccine Type, Brand, Age Group, End User)
  • UK
  • Germany
  • Spain
  • France
  • Italy
  • Rest of Europe
• Asia-Pacific (Vaccine Type, Brand, Age Group, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America (Vaccine Type, Brand, Age Group, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Vaccine Type, Brand, Age Group, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CSL Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Serum Institute of India Pvt. Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biomed Pvt. Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bharat Biotech
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biological E. Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hualan Biological Engineering Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Walvax Biotechnology Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Chongqing Zhifei Biological Products Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Emergent BioSolutions Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Incepta Vaccine Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Panacea Biotec Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• LG Chem Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mitsubishi Tanabe Pharma Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Valneva SE
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vaxart, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendation